William Blair reissued their outperform rating on shares of FibroGen, Inc (NASDAQ:FGEN) in a research report sent to investors on Wednesday. William Blair also issued estimates for FibroGen’s Q3 2017 earnings at ($0.45) EPS, FY2017 earnings at ($2.02) EPS, Q1 2018 earnings at ($0.72) EPS, Q2 2018 earnings at ($0.69) EPS, Q3 2018 earnings at $0.86 EPS, Q4 2018 earnings at ($0.62) EPS and FY2018 earnings at ($1.17) EPS.
FGEN has been the topic of several other research reports. Citigroup Inc. upped their price target on FibroGen from $48.00 to $65.00 and gave the stock a top pick rating in a research note on Tuesday. BidaskClub downgraded FibroGen from a strong-buy rating to a buy rating in a research note on Monday, July 31st. Jefferies Group LLC assumed coverage on FibroGen in a research note on Monday, July 10th. They issued a buy rating and a $50.00 price target on the stock. Stifel Nicolaus restated a buy rating and issued a $38.00 price target (up previously from $32.00) on shares of FibroGen in a research note on Thursday, June 22nd. Finally, Goldman Sachs Group, Inc. (The) downgraded FibroGen from a buy rating to a neutral rating and set a $31.00 price target on the stock. in a research note on Friday, July 21st. One analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $60.17.
Shares of FibroGen (NASDAQ FGEN) traded up 1.34% on Wednesday, hitting $41.65. The company had a trading volume of 1,005,368 shares. FibroGen has a 52 week low of $15.60 and a 52 week high of $51.70. The stock’s market capitalization is $2.97 billion. The firm’s 50 day moving average price is $34.92 and its 200-day moving average price is $28.29.
FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.01. The company had revenue of $29 million during the quarter, compared to analysts’ expectations of $34.80 million. FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. Analysts forecast that FibroGen will post ($1.82) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was reported by Stock Observer and is owned by of Stock Observer. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.thestockobserver.com/2017/08/12/fibrogen-inc-nasdaqfgen-earns-outperform-rating-from-william-blair.html.
In other FibroGen news, CEO Thomas B. Neff sold 38,636 shares of the stock in a transaction on Wednesday, May 31st. The stock was sold at an average price of $26.21, for a total transaction of $1,012,649.56. Following the sale, the chief executive officer now directly owns 3,345,941 shares in the company, valued at approximately $87,697,113.61. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Kalevi Kurkijarvi sold 2,000 shares of the stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $27.40, for a total value of $54,800.00. Following the sale, the director now owns 36,000 shares in the company, valued at $986,400. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 537,474 shares of company stock worth $19,220,138. Company insiders own 14.90% of the company’s stock.
A number of hedge funds have recently modified their holdings of the stock. Parametric Portfolio Associates LLC increased its stake in shares of FibroGen by 44.2% in the second quarter. Parametric Portfolio Associates LLC now owns 14,590 shares of the biopharmaceutical company’s stock valued at $471,000 after buying an additional 4,470 shares in the last quarter. Piermont Capital Management Inc. acquired a new stake in shares of FibroGen during the second quarter valued at approximately $636,000. Quantbot Technologies LP acquired a new stake in shares of FibroGen during the second quarter valued at approximately $128,000. California Public Employees Retirement System increased its stake in shares of FibroGen by 2.2% in the second quarter. California Public Employees Retirement System now owns 93,200 shares of the biopharmaceutical company’s stock valued at $3,010,000 after buying an additional 2,000 shares in the last quarter. Finally, FMR LLC increased its stake in shares of FibroGen by 96.9% in the second quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock valued at $107,753,000 after buying an additional 1,641,423 shares in the last quarter. Institutional investors and hedge funds own 43.45% of the company’s stock.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.